Creo Medical (LSE:CREO) has increased its revenue growth expectations for FY26 after a strong start to the financial year, with first-quarter revenue rising by around 60% compared with the same period last year. The company said continued commercial momentum, driven by higher procedural volumes and growing clinical adoption of its technologies, has prompted it to tighten its full-year guidance to the upper end of its previous forecast, with revenue now expected to increase by 50% to 60% versus FY25.
The company reported broader uptake of its core product portfolio, including Speedboat, SpydrBlade Flex and MicroBlate Fine, reflecting increasing engagement from clinicians across its target markets. Alongside expanding sales, Creo is implementing measures to strengthen its financial position by outsourcing manufacturing, a move expected to reduce annual operating costs by more than £1 million. The group has also raised £5.5 million through a share placing and secured a further £2 million in convertible loan funding, providing additional resources to support inventory, commercial expansion and progress towards sustainable cash generation and profitability.
While operational momentum continues to improve, Creo’s investment outlook remains constrained by ongoing operating losses and negative operating and free cash flow. The company nevertheless benefits from a relatively modest debt position, and technical indicators remain supportive, with the shares trading above several key moving averages. Combined with an undemanding valuation based on earnings expectations, these factors contribute to a more constructive overall assessment despite the business remaining in an investment phase.
More about Creo Medical
Creo Medical Group is a UK-based medical technology company focused on developing minimally invasive electrosurgical devices for endoscopic procedures, particularly in the treatment of pre-cancerous conditions and cancer. Its CROMA platform, powered by Kamaptive adaptive energy technology, combines bipolar radiofrequency and microwave energy to enable precise cutting, coagulation and tissue ablation, with the aim of improving clinical outcomes while reducing the complexity, invasiveness and cost of surgical procedures.
Leave a Reply